Market Cap | 1.39B | P/E | - | EPS this Y | -9.90% | Ern Qtrly Grth | - |
Income | -96.75M | Forward P/E | -13.64 | EPS next Y | -51.00% | 50D Avg Chg | -25.00% |
Sales | - | PEG | -1.56 | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 3.60 | EPS next 5Y | 40.00% | 52W High Chg | -46.00% |
Recommedations | 1.50 | Quick Ratio | 37.55 | Shares Outstanding | 110.80M | 52W Low Chg | 449.00% |
Insider Own | 6.03% | ROA | -11.57% | Shares Float | 104.78M | Beta | 1.00 |
Inst Own | 75.17% | ROE | -14.80% | Shares Shorted/Prior | 15.91M/17.70M | Price | 13.91 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 2,851,827 | Target Price | 113.55 |
Oper. Margin | - | Earnings Date | Oct 23 | Volume | 1,253,300 | Change | -1.77% |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Lian Brian | President & CEO President & CEO | Jan 31 | Sell | 24.7 | 85,000 | 2,099,500 | 2,264,882 | 01/31/24 |
Lian Brian | President & CEO President & CEO | Jan 31 | Option | 1.23 | 85,000 | 104,550 | 2,349,882 | 01/31/24 |
Lian Brian | President & CEO President & CEO | Jan 30 | Sell | 23.95 | 35,000 | 838,250 | 2,264,882 | 01/30/24 |
Lian Brian | President & CEO President & CEO | Jan 30 | Option | 1.23 | 35,000 | 43,050 | 2,299,882 | 01/30/24 |
Rouan Sarah Kathryn | Director Director | Jan 19 | Sell | 23.05 | 30,000 | 691,500 | 01/19/24 | |
Rouan Sarah Kathryn | Director Director | Jan 19 | Option | 8.32 | 30,000 | 249,600 | 30,000 | 01/19/24 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Jan 03 | Sell | 17.9 | 15,000 | 268,500 | 180,730 | 01/04/24 |
Rowland Charles A Jr | Director Director | May 16 | Option | 1.08 | 40,000 | 43,200 | 70,000 | 05/18/23 |
Rowland Charles A Jr | Director Director | May 16 | Sell | 25 | 40,000 | 1,000,000 | 30,000 | 05/18/23 |
MACARTNEY LAWSON | Director Director | May 16 | Sell | 24 | 16,000 | 384,000 | 47,965 | 05/18/23 |
MACARTNEY LAWSON | Director Director | May 16 | Option | 1.19 | 16,000 | 19,040 | 63,965 | 05/18/23 |
Lian Brian | President & CEO President & CEO | May 01 | Sell | 22.45 | 45,000 | 1,010,250 | 2,197,963 | 05/01/23 |
MACARTNEY LAWSON | Director Director | Apr 24 | Sell | 22 | 16,000 | 352,000 | 47,965 | 04/24/23 |
MACARTNEY LAWSON | Director Director | Apr 24 | Option | 3.33 | 16,000 | 53,280 | 63,965 | 04/24/23 |
Lian Brian | President & CEO President & CEO | Apr 19 | Sell | 21.45 | 35,000 | 750,750 | 2,242,963 | 04/21/23 |
MACARTNEY LAWSON | Director Director | Apr 17 | Sell | 20 | 20,786 | 415,720 | 47,965 | 04/18/23 |
MACARTNEY LAWSON | Director Director | Apr 17 | Option | 8 | 20,786 | 166,288 | 68,751 | 04/18/23 |
Lian Brian | President & CEO President & CEO | Apr 17 | Sell | 20.45 | 155,000 | 3,169,750 | 2,277,963 | 04/18/23 |
Lian Brian | President & CEO President & CEO | Apr 17 | Option | 2.15 | 125,000 | 268,750 | 2,432,963 | 04/18/23 |
Mancini Marianna | Chief Operating Offi.. Chief Operating Officer | Apr 17 | Sell | 20 | 12,500 | 250,000 | 287,763 | 04/18/23 |
Mancini Marianna | Chief Operating Offi.. Chief Operating Officer | Apr 17 | Option | 13.07 | 12,500 | 163,375 | 300,263 | 04/18/23 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Apr 17 | Sell | 20 | 7,500 | 150,000 | 149,279 | 04/18/23 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Apr 17 | Option | 13.07 | 7,500 | 98,025 | 156,779 | 04/18/23 |
Lian Brian | President & CEO President & CEO | Apr 13 | Sell | 18.45 | 79,336 | 1,463,749 | 2,307,963 | 04/13/23 |
Lian Brian | President & CEO President & CEO | Apr 13 | Option | 1.88 | 54,336 | 102,152 | 2,387,299 | 04/13/23 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Apr 11 | Sell | 18 | 97,839 | 1,761,102 | 149,279 | 04/13/23 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Apr 11 | Option | 6.12 | 97,839 | 598,775 | 190,823 | 04/13/23 |
Lian Brian | President & CEO President & CEO | Mar 30 | Sell | 17.43 | 243,352 | 4,241,625 | 2,232,963 | 04/03/23 |
Lian Brian | President & CEO President & CEO | Mar 30 | Option | 6.74 | 203,352 | 1,370,592 | 2,322,933 | 04/03/23 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Mar 30 | Sell | 17.5 | 161,940 | 2,833,950 | 147,778 | 04/03/23 |
ZANTE GREG | Chief Financial Offi.. Chief Financial Officer | Mar 30 | Option | 6.55 | 124,661 | 816,530 | 178,689 | 04/03/23 |
Mancini Marianna | Chief Operating Offi.. Chief Operating Officer | Mar 30 | Option | 9.92 | 72,200 | 716,224 | 261,895 | 04/03/23 |
Mancini Marianna | Chief Operating Offi.. Chief Operating Officer | Mar 28 | Sell | 15.5 | 237,805 | 3,685,978 | 261,895 | 03/30/23 |
Mancini Marianna | Chief Operating Offi.. Chief Operating Officer | Mar 28 | Option | 2.98 | 182,427 | 543,632 | 303,137 | 03/30/23 |